Leonid Temkin, MD
Pain Medicine · Sanford, MENPI 1801881362
Payments from drug & device makers
What this record shows
Boston Scientific accounts for 87.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $1,797 and has fallen 91.5% since, to $153 in 2025. Among pain medicine clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $80.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Nevro Corp.$478
- SPR Therapeutics, Inc$81
What the payments were for
- Travel & lodging$1,93442%
- Food & beverage$2,67358%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 43 | $4,048 |
| Nevro Corp. | 13 | $478 |
| SPR Therapeutics, Inc | 1 | $81 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,607 in reported general payments places this provider in the 90th percentile of 20 pain medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 108 | $80,935 |
| Xtampza ErOxycodone Myristate | 81 | $36,095 |
| Buprenorphine | 116 | $27,898 |
| LinzessLinaclotide | 15 | $16,539 |
| OxycontinOxycodone Hcl | 37 | $15,264 |
| MovantikNaloxegol Oxalate | 11 | $8,919 |
| Hysingla ErHydrocodone Bitartrate | 21 | $7,154 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 277 | $6,774 |
| Oxycodone Hcl | 306 | $5,195 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 136 | $3,997 |
| Pregabalin | 81 | $3,641 |
| Fentanyl | 34 | $2,971 |
| Methadone Hcl | 165 | $2,060 |
| Celecoxib | 27 | $1,922 |
| Gabapentin | 61 | $1,826 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Sanford
- Muhammad KhanSanford$79
- Yussr IbrahimBangor$30K
- Campbell Belisle HaleyKennebunk$3K
- Christine KerrScarborough$2K
- Isaac ChemmanamPortland$2K
- Syena SarrafpourPortland$1K
- John HallScarborough$608
- Rita TenMachias$393
- Peter MarshallBangor$352
- Gregory FoosScarborough$269
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.